A Review of Fluvoxamine and its Uses in Depression

Burton, Stephen W.

doi:10.1097/00004850-199112003-00001

Cited by 31 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accumulated experience with fluvoxamine in controlled clinical trials has shown that it is effective as a conventional tricyclic antidepressant (Burton, 1991). However, many patients who suffer from depression have concomitant morbidity with conditions such as obsessive‐compulsive disorder, anxiety disorders and, to some extent, panic disorders.…”

Section: The Psychiatric Studymentioning

confidence: 99%

A Local Influence Approach Applied to Binary Data from a Psychiatric Study

Jansen¹,

Molenberghs

Aerts³

et al. 2003

Biometrics

View full text Add to dashboard Cite

Recently, a lot of concern has been raised about assumptions needed in order to fit statistical models to incomplete multivariate and longitudinal data. In response, research efforts are being devoted to the development of tools that assess the sensitivity of such models to often strong but always, at least in part, unverifiable assumptions. Many efforts have been devoted to longitudinal data, primarily in the selection model context, although some researchers have expressed interest in the pattern-mixture setting as well. A promising tool, proposed by Verbeke et al. (2001, Biometrics 57, 43-50), is based on local influence (Cook, 1986, Journal of the Royal Statistical Society, Series B 48, 133-169). These authors considered the Diggle and Kenward (1994, Applied Statistics 43, 49-93) model, which is based on a selection model, integrating a linear mixed model for continuous outcomes with logistic regression for dropout. In this article, we show that a similar idea can be developed for multivariate and longitudinal binary data, subject to nonmonotone missingness. We focus on the model proposed by Baker, Rosenberger, and DerSimonian (1992, Statistics in Medicine 11, 643-657). The original model is first extended to allow for (possibly continuous) covariates, whereafter a local influence strategy is developed to support the model-building process. The model is able to deal with nonmonotone missingness but has some limitations as well, stemming from the conditional nature of the model parameters. Some analytical insight is provided into the behavior of the local influence graphs.

show abstract

Section: The Psychiatric Studymentioning

confidence: 99%

A Local Influence Approach Applied to Binary Data from a Psychiatric Study

Jansen¹,

Molenberghs

Aerts³

et al. 2003

Biometrics

View full text Add to dashboard Cite

show abstract

“…Although effective for the treatment of depression in adults, [178,179] it is currently labelled only for use in obsessive-compulsive disorder in adults and children ≥8 years of age.…”

Section: Fluvoxaminementioning

confidence: 99%

Pharmacological Treatment of Depression in Children and Adolescents

1999

View full text Add to dashboard Cite

Major depression is a common disorder during childhood and adolescence. Over the past decade, many new antidepressants have been marketed in the US. In adults, these newer agents have been shown to be as effective as the prototypic tricyclic antidepressants (TCAs). Further, when compared with the TCAs these medications are better tolerated and are safer in overdose. Although TCAs are effective in the treatment of depressed adults, controlled clinical trials have not demonstrated their efficacy in either children or adolescents. In addition, concerns about the safety of TCAs and the monoamine oxidase inhibitors has left disappointingly few pharmacological treatment options available for depressed children and adolescents. For this reason, clinicians have begun to prescribe the newer agents for this population, despite the fact that relatively little is known about their disposition, safety or effectiveness in the young. Investigators have begun to examine whether the use of newer antidepressant medications such as fluoxetine, sertraline, paroxetine, fluvoxamine, nefazodone, and venlafaxine is truly indicated for children and adolescents with major depression. Pharmacokinetic studies of sertraline, paroxetine and nefazodone have been performed in depressed youths. The results of these studies have provided data for rational administration strategies for these agents. They have also provided evidence that these agents may be well tolerated in children and adolescents. Further evidence that these agents are often well tolerated when prescribed to depressed youths has been obtained from both open-label and double-blind studies. Published studies have generally shown that open-label treatment with these newer agents often leads to symptom amelioration in paediatric patients with major depression. Since high rates of placebo response are often seen in depressed children and adolescents, results from these studies cannot be interpreted to suggest that these medications have true antidepressant efficacy in this population. At present, the results of only two such studies have been published. The results of one of these trials are difficult to interpret because of methodological considerations. The other study reported that treatment with fluoxetine was superior to placebo. This paper critically reviews what has been published about the pharmacological treatment of depressed paediatric patients and provides some guidance to the use of antidepressants in this patient population, paying particular attention to what is known about the newer antidepressants as well as considering directions for future research.

show abstract

“…Burton (1991) reviewed 17 double-blind comparative studies between fluvoxamine and other ADs in depressed patients. The review, however, was limited to published materials (publication bias not eliminated) and study inclusion criteria, data sources and validity assessment were not reported.…”

Section: Introductionmentioning

confidence: 99%

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis

et al. 2008

View full text Add to dashboard Cite

Fluvoxamine, one of the oldest selective serotonin reuptaking inhibitors, is commonly prescribed to patients with major depression. Several studies have reviewed the efficacy and tolerability of fluvoxamine for the treatment of major depression. However, these reviews are outdated, have not been systematic and/or suffered from several methodological weaknesses. We conducted a systematic review to synthesize the best available evidence on the efficacy of fluvoxamine for adult patients suffering from major depression in comparison with other active antidepressive agents. Relevant randomized controlled trials were identified through a comprehensive search. The primary outcome was a relative risk of response, and the secondary outcome was a relative risk of remission. Tolerability and side-effect profile were also examined. Fifty-three trials were included. There were no large differences between fluvoxamine and any other antidepressants in terms of efficacy and tolerability. There is evidence of differing side effect profiles, especially when comparing gastrointestinal side effects between fluvoxamine and tricyclics. Clinicians should focus on practically or clinically relevant differences including those in side-effect profiles.

show abstract

A Review of Fluvoxamine and its Uses in Depression

Cited by 31 publications

References 0 publications

A Local Influence Approach Applied to Binary Data from a Psychiatric Study

A Local Influence Approach Applied to Binary Data from a Psychiatric Study

Pharmacological Treatment of Depression in Children and Adolescents

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis

Contact Info

Product

Resources

About